Switch theme
Sign up to access all valuation multiples
DexTech Medical AB develops candidate medications with applications within urological oncology, for prostate cancer. Its medication candidates include GuaDex, OsteoDex, and SomaDex, among others. The company conducts operations in medical research with the development of new drug candidates mainly in urological oncology, but also other cancer diseases and for non-malignant diseases. The company has a well built clinical base with valuable specialist expertise from research laboratories and manufacturing to clinical oncology.
2004
1
Last FY Revenue n/a
Last FY EBITDA -$0.2M
$8.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, DexTech Medical achieved revenue of n/a and an EBITDA of -$0.2M.
DexTech Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See DexTech Medical valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | XXX | $0.6M | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$0.2M | XXX | XXX | XXX |
| EBITDA Margin | XXX | n/a | XXX | XXX | XXX |
| EBIT | XXX | -$0.6M | XXX | XXX | XXX |
| EBIT Margin | XXX | n/a | XXX | XXX | XXX |
| Net Profit | XXX | -$0.5M | XXX | XXX | XXX |
| Net Margin | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, DexTech Medical's stock price is SEK 5 (or $1).
DexTech Medical has current market cap of SEK 96.1M (or $9.9M), and EV of SEK 80.5M (or $8.3M).
See DexTech Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.3M | $9.9M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, DexTech Medical has market cap of $9.9M and EV of $8.3M.
DexTech Medical's trades at n/a EV/Revenue multiple, and -43.3x EV/EBITDA.
Equity research analysts estimate DexTech Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
DexTech Medical's P/E ratio is not available.
See valuation multiples for DexTech Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9.9M | XXX | $9.9M | XXX | XXX | XXX |
| EV (current) | $8.3M | XXX | $8.3M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -43.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -14.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -20.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -13.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDexTech Medical's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.1M for the same period.
DexTech Medical's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
DexTech Medical's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for DexTech Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
DexTech Medical acquired XXX companies to date.
Last acquisition by DexTech Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . DexTech Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was DexTech Medical founded? | DexTech Medical was founded in 2004. |
| Where is DexTech Medical headquartered? | DexTech Medical is headquartered in Sweden. |
| How many employees does DexTech Medical have? | As of today, DexTech Medical has 1 employees. |
| Is DexTech Medical publicy listed? | Yes, DexTech Medical is a public company listed on SAT. |
| What is the stock symbol of DexTech Medical? | DexTech Medical trades under DEX ticker. |
| When did DexTech Medical go public? | DexTech Medical went public in 2014. |
| Who are competitors of DexTech Medical? | Similar companies to DexTech Medical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of DexTech Medical? | DexTech Medical's current market cap is $9.9M |
| Is DexTech Medical profitable? | Yes, DexTech Medical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
